ARCHIVES

In Vote Against Tarceva As Maintenance, ODAC Seeks Stronger Survival Benefit

This article is from The Cancer Letter archive.

Vol. 35 No. 46 | December 18, 2009

Download PDF Visit The Full Archive

Related Articles

The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power

October 31, 2014

NCI Audit Finds “Low Quality” Research At Calif. Foundation

June 17, 1994

RFAs Available

February 23, 1996

DRCCA Board Cool On communications Network, Hears Report On Behavior Program

May 21, 1982

Celgene Begins Two Studies With Hoffmann-La Roche.

June 29, 2001

ImClone Protocol Generates More Questions Than Answers

March 8, 2002